
Encaleret boosts bone turnover and improves symptoms in ADH1 patients, with FDA Priority Review underway.
BridgeBio Pharma announced that encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial. 100% of patients on encaleret reported symptom im...





